| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 161.87 | 0.17 (+0.11%) | 135.77 - 194.44 | 243.9 thousand |
Market data as of 4:02PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 162.37 |
|---|---|
| Previous Close | 161.70 |
| Day's Range | 161.78 - 163.02 |
| Market Cap | 69.9B |
| Avg Volume (10 Day) | 248.4K |
| Price/Earnings (Trailing 12 Mo.) | 22.1x |
| Earnings Per Share (Trailing 12 Mo.) | 7.3 |
| Dividend Yield | 3.18 (1.97%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Pass |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Pass |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Victoza® (liraglutide [rDNA origin] injection) safety profile further supported at scientific workshop on pancreatitis, diabetes and pancreatic cancer
PR Newswire - Thursday 06/13/2013 7:05 PM ET
| NVO | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 16.98% | |
| Net Income Growth (1yr) | 28.14% | |
| Total Debt/Equity | 0.01 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 4.52% | |
| Price/Sales | 6.29 |
| Company | Last | Change |
|---|---|---|
| Teva Pharmaceutical Industries Ltd | 39.64 | +0.81% |
| Allergan Inc | 101.49 | +0.01% |
| Forest Laboratories Inc | 41.57 | +0.70% |
| Pharmacyclics Inc | 88.26 | +1.23% |
| Dr.Reddy's Laboratories Ltd | 36.71 | -0.73% |
Data is delayed by at least 15 min.